| Similar Articles |
|---|
 |
The Motley Fool
April 27, 2007
Rich Smith |
Foolish Forecast: ViaCell Doing Swell? The cord blood specialist is set to release its first-quarter 2007 earnings. Investors, here is what you can expect to see.   |
The Motley Fool
August 2, 2006
Rich Smith |
Foolish Forecast: Anemic ViaCell The cord blood storage specialist is due to report its second quarter 2006 numbers tomorrow. Investors, take note. |
The Motley Fool
September 20, 2005
Rich Smith |
ViaCell's Cancer Trial Snag The cord blood collector suffers a research setback. Investors should keep in mind that the real money-maker behind ViaCell is its ViaCord cord blood storage business. |
The Motley Fool
November 8, 2005
Rich Smith |
ViaCell Looks Healthier The cord blood collector reports narrowing losses. Investors, take note. |
The Motley Fool
May 4, 2006
Rich Smith |
ViaCell Looking Sickly As expected, the company remains solvent by virtue of one division: its ViaCord umbilical cord blood storage unit, which provided $11.9 million of the quarter's $12.1 million in revenues. But even that good news fails to outweigh the bad news. Investors, take note. |
BusinessWeek
June 27, 2005
Arlene Weintraub |
Stem Cells To Go ViaCell's goal is to mass-produce stem cells from umbilical cord blood. |
The Motley Fool
August 13, 2007
Rich Smith |
ViaCell Sees the Light Despite rising sales at its trademark ViaCord umbilical cord blood storage service, and gross margin from this service rising in tandem, the firm's operating and net results remain mired in thick red ink. Investors, take note. |
The Motley Fool
February 26, 2007
Rich Smith |
Foolish Forecast: Cryo-Cell Defrosting The cord-blood storage specialist will report its fourth-quarter and full-year financial news shortly. Investors, here is what you can expect to see. |
The Motley Fool
August 8, 2007
Rich Smith |
Foolish Forecast: Watch for ViaCell to Tip Its Hand Will second-quarter results from cord-blood storage specialist ViaCell meet or exceed the relatively low management expectations? And will the next quarter improve, as the company has previously predicted? |
The Motley Fool
April 18, 2005
Rich Smith |
U.S. Government Out for Blood Two companies await as the Institute of Medicine advocates improvements in cord blood banking. Newly public ViaCell has been plummeting along with rival Cryo-Cell, down roughly 40% over the past three months. |
The Motley Fool
October 2, 2007
Brian Orelli |
PerkinElmer and ViaCell: A Bloody Good Deal? PerkinElmer buys umbilical cord storage company ViaCell for $300 million. Investors, take note; the merger may be a good fit for both companies. |
The Motley Fool
March 2, 2005
Rich Smith |
ViaCell Under the Microscope Cord blood collector makes its first earnings announcement tomorrow. Investors will likely be shining harsh lights on the company's financial statements. |
The Motley Fool
May 1, 2007
Rich Smith |
The Losses Swell at ViaCell Given that ViaCell has been ramping up its sales and marketing spending for about a year, it's about time ViaCell's stock start showing some results from this "investment." |
The Motley Fool
March 5, 2007
Rich Smith |
ViaCell Not Doing Well The company's biotech half continues to sap revenue from the moneymaking side. Investors, take note. |
The Motley Fool
November 30, 2004
Rich Smith |
Breaking Rules and Saving Lives Cord blood offers an ethical means of using stem cells to heal illness. While two top companies in the field are private, over the counter traded Cryo-Cell lost as much money as it collected in revenues last year. |
The Motley Fool
September 5, 2006
Rich Smith |
Foolish Forecast: ThermoGenesis Begins The medical equipment maker is due to report fiscal fourth-quarter and full-year 2006 numbers. Will they chill or warm investors hearts? |
The Motley Fool
January 25, 2005
Rich Smith |
ViaCell's Costly Mistake Cord blood harvester neglects to collect the cash with an undervalued IPO. |
The Motley Fool
January 4, 2005
Rich Smith |
Blood for Sale Cord blood harvester ViaCell moves closer to its IPO, with pricing to be in the $7 to $9 range and will float 7.5 million shares, though still on a date "to be announced." |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
Salon.com
July 17, 2000
Alix Christie |
The cord-blood controversy First we were supposed to eat the placenta. Now we're supposed to freeze it. |
The Motley Fool
April 3, 2006
Seth Jayson |
No Stemming the Flow of Shares Another year, another large dollop of shares to water down the juice at StemCells. This company excels at burning money, as its cash flow statements show. Invest accordingly. |
The Motley Fool
August 8, 2006
Rich Smith |
Second Opinion on ViaCell The prognosis isn't good. Is there still hope for ViaCell? Of course! Hope springs eternal. If ViaCell can just tighten its purse strings, investors may yet find a way to save blood and make money. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
The Motley Fool
October 14, 2005
Tim Beyers |
Baby Breaker Birth Announcements We track the week in private equity in search of investments of the future. Virxsys... Raven Biotechnologies... |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
The Motley Fool
March 2, 2007
Rich Smith |
Cryo-Cell Melts Cryo-Cell reversed its history of generating cash profits. In contrast to the $2.4 million in cold, hard cash added to its coffers in 2005, the firm burned through about $71,000 in 2006. Investors, take note. |
The Motley Fool
December 29, 2005
Rich Smith |
New Year's 2016: Four Fabulous Fads Today's passing fads are tomorrow's market dominators. Investing is already more art than science, and investing for 10 years in the future -- even more so. |
The Motley Fool
July 14, 2011
Rich Smith |
What's All the Fuss About Stem Cells? Stocks are up on news of Sweden's miracle meatball. Over the weekend, Swedish researchers announced the successful transplant of an artificial trachea to a patient whose own organ had been ravaged by cancer. |
